Short answer
Bio-Techne (TECH) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $300M (up 4.6% year over year) with net income of $28M.
Q3 2026 key financials · XBRL
- Revenue
- $300M
- +4.6% YoY
- Net income
- $28M
- −25.9% YoY
- Operating margin
- 12.2%
- Gross margin
- 65.6%
- EPS (diluted)
- $0.18
- −25.0% YoY
Source: XBRL data from the Bio-Techne (TECH) Q3 2026 10-Q on SEC EDGAR. USD.
Bio-Techne Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $299.7M, up 5% YoY from $286.6M
- Gross margin 65.6% vs 65.6% YoY, adjusted margin 69.3% vs 70.2%
- Protein Sciences best performer: sales $219.7M, up 9%; operating margin 37.9% vs 38.4%
- Diagnostics and Spatial Biology weakest: sales $80.2M, up 1%; operating margin 7.4% vs 11.2%
- Cash $350.0M vs $264.7M; operating cash flow $73.1M vs $27.6M, capital expenditures $5.9M and $12.6M dividends
Risk Factors
- No material changes to previously disclosed risk factors during the quarter ended September 30, 2026
- Carried-forward risks include macroeconomic conditions affecting demand and operating results
- Carried-forward risks include competition and technological change in life-science markets
- Carried-forward risks include liquidity, debt, and foreign-currency exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-Techne quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.